View in EDS

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

Saved in:
Bibliographic Details
Title: MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.
Authors: Hurvitz N; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Amitai I; Hematology Division, Chaim Sheba Medical Center, Gray Faculty of Medical & Health Sciences, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Yurkovski IL; Hematology Division, Bnai Zion Medical Canter, Haifa, Israel.; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel., Tvito A; Hematology and Stem Cell Transplantation Department and the Eisenberg RD Authority, Shaare Zedek Medical Center, Hebrew University Jerusalem, Jerusalem, Israel., Ofran Y; Hematology and Stem Cell Transplantation Department and the Eisenberg RD Authority, Shaare Zedek Medical Center, Hebrew University Jerusalem, Jerusalem, Israel., Porges T; Institute of Hematology, Soroka University Medical Center, Beer Sheva, Israel., Wolach O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Gray Faculty of Medical & Health Sciences, Faculty of Medicine, Tel Aviv University, Petah-Tikva, Israel., Sherban A; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Gray Faculty of Medical & Health Sciences, Faculty of Medicine, Tel Aviv University, Petah-Tikva, Israel., Even-Zohar NG; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Vainstein V; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Haran A; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Aumann S; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Mikhelashvili R; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Frisch A; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel., Nachmias B; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. BoazN@hadassah.org.il.
Source: Annals of hematology [Ann Hematol] 2026 May 09; Vol. 105 (7). Date of Electronic Publication: 2026 May 09.
Publication Type: Journal Article; Multicenter Study; Observational Study
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42104100
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hurvitz+N%22">Hurvitz N</searchLink>; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Amitai+I%22">Amitai I</searchLink>; Hematology Division, Chaim Sheba Medical Center, Gray Faculty of Medical & Health Sciences, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Yurkovski+IL%22">Yurkovski IL</searchLink>; Hematology Division, Bnai Zion Medical Canter, Haifa, Israel.; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.<br /><searchLink fieldCode="AU" term="%22Tvito+A%22">Tvito A</searchLink>; Hematology and Stem Cell Transplantation Department and the Eisenberg RD Authority, Shaare Zedek Medical Center, Hebrew University Jerusalem, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Ofran+Y%22">Ofran Y</searchLink>; Hematology and Stem Cell Transplantation Department and the Eisenberg RD Authority, Shaare Zedek Medical Center, Hebrew University Jerusalem, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Porges+T%22">Porges T</searchLink>; Institute of Hematology, Soroka University Medical Center, Beer Sheva, Israel.<br /><searchLink fieldCode="AU" term="%22Wolach+O%22">Wolach O</searchLink>; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Gray Faculty of Medical & Health Sciences, Faculty of Medicine, Tel Aviv University, Petah-Tikva, Israel.<br /><searchLink fieldCode="AU" term="%22Sherban+A%22">Sherban A</searchLink>; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Gray Faculty of Medical & Health Sciences, Faculty of Medicine, Tel Aviv University, Petah-Tikva, Israel.<br /><searchLink fieldCode="AU" term="%22Even-Zohar+NG%22">Even-Zohar NG</searchLink>; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Vainstein+V%22">Vainstein V</searchLink>; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Haran+A%22">Haran A</searchLink>; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Aumann+S%22">Aumann S</searchLink>; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Mikhelashvili+R%22">Mikhelashvili R</searchLink>; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Frisch+A%22">Frisch A</searchLink>; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.<br /><searchLink fieldCode="AU" term="%22Nachmias+B%22">Nachmias B</searchLink>; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. BoazN@hadassah.org.il.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229107334%22">Annals of hematology</searchLink> [Ann Hematol] 2026 May 09; Vol. 105 (7). <i>Date of Electronic Publication: </i>2026 May 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Multicenter Study; Observational Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>9107334 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0584 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209395555%22">09395555 </searchLink><i>NLM ISO Abbreviation: </i>Ann Hematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42104100
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00277-026-07054-5
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hurvitz N
      – PersonEntity:
          Name:
            NameFull: Amitai I
      – PersonEntity:
          Name:
            NameFull: Yurkovski IL
      – PersonEntity:
          Name:
            NameFull: Tvito A
      – PersonEntity:
          Name:
            NameFull: Ofran Y
      – PersonEntity:
          Name:
            NameFull: Porges T
      – PersonEntity:
          Name:
            NameFull: Wolach O
      – PersonEntity:
          Name:
            NameFull: Sherban A
      – PersonEntity:
          Name:
            NameFull: Even-Zohar NG
      – PersonEntity:
          Name:
            NameFull: Vainstein V
      – PersonEntity:
          Name:
            NameFull: Haran A
      – PersonEntity:
          Name:
            NameFull: Aumann S
      – PersonEntity:
          Name:
            NameFull: Mikhelashvili R
      – PersonEntity:
          Name:
            NameFull: Frisch A
      – PersonEntity:
          Name:
            NameFull: Nachmias B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 05
              Text: 2026 May 09
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0584
          Numbering:
            – Type: volume
              Value: 105
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Annals of hematology
              Type: main
ResultId 1